Publication details

Katetrizační ablace fibrilace síní a přímá antikoagulancia

Title in English Catheter ablation in atrial fibrillation and direct anticoagulants

ŠPINAR Jindřich LÁBROVÁ Růžena

Year of publication 2017
Type Article in Periodical
Magazine / Source Kardiologická revue - Interní medicína
MU Faculty or unit

Faculty of Medicine

Field Cardiovascular diseases incl. cardiosurgery
Keywords anticoagulation; atrial fibrillation; ablation; safety
Description Direct anticoagulants (blockers of factor II or factor Xa) have become a routine part of clinical practice and have replaced coumarine blockers (warfarin) in many indications, providing a more beneficial and safer effect. The main indications are non-valvular atrial fibrillation, deep venous thrombosis and lung embolism. New information are available in their uninterrupted use during catheter ablation of atrial fibrillation. The VENTURE AF study has shown non-inferiority of rivaroxaban vs. warfarin in 248 patients undergoing ablation of atrial fibrillation. The RE-CIRCUIT study compared the treatment with dabigatran and warfarin in 704 patients undergoing ablation of atrial fibrillation and has shown a superiority of dabigatran, especially in terms of its safety profile, as dabigatran treatment was associated with lower incidence of bleeding.

You are running an old browser version. We recommend updating your browser to its latest version.

More info